Advertisment

Key Insights from the San Antonio Breast Cancer Symposium 2023

author-image
Dr. Jessica Nelson
New Update
Key Insights from the San Antonio Breast Cancer Symposium 2023

Key Insights from the San Antonio Breast Cancer Symposium 2023

Advertisment

The 46th San Antonio Breast Cancer Symposium (SABCS) 2023, a landmark event in the field of breast cancer research, concluded successfully. Approximately 10,000 people attended the event, and over 1,700 new scientific abstracts were shared. The event was marked by a focus on precision treatment and de-escalation, advocating for individually tailored treatment and a 'less is more' mindset regarding therapies.

Advertisment

Groundbreaking Trials and Treatments

New data from the HER2CLIMB 02 trial were presented, revealing promising results for a new drug combination for metastatic HER2 breast cancer patients. The trial demonstrated improved progression-free survival for patients with the combination of tucatinib and trastuzumab emtansine. In another phase 2a investigation, the bispecific monoclonal antibody Zanidatamab, in combination with the CDK4/6 inhibitor palbociclib and the anti-hormone drug fulvestrant, showed exciting efficacy results in patients with HER2 and ER or triple-positive metastatic breast cancer.

Key Studies and Their Findings

Advertisment

The extended follow-up of the PARSIFAL study evaluated the optimal endocrine partner for palbociclib for patients with endocrine-sensitive hormone receptor-positive HER2-negative HR HER2 advanced breast cancer. The ATRACTIB clinical trial evaluated the efficacy and safety of first-line atezolizumab, bevacizumab, and paclitaxel in patients with advanced triple-negative breast cancer (TNBC). The combination demonstrated significant antitumor activity with a median progression-free survival of 11 months. Another study, the DEBBRAH trial, showed promising antitumor activity of trastuzumab deruxtecan with a median overall survival of 13.3 months in patients with HER2 or HER2 low advanced breast cancer with leptomeningeal carcinomatosis. The MiRaDor trial aims to monitor minimal residual disease (MRD) through circulating tumor DNA (ctDNA) to determine treatment efficacy in high-risk patients.

The Impact of Immunotherapy and Personalized Medicine

A significant part of the symposium was dedicated to new research on targeted therapies, immunotherapy, and personalized medicine for breast cancer treatment. Key findings included the effectiveness of a new drug in treating HER2-positive breast cancer, the potential of immunotherapy in TNBC, and the importance of genetic testing for guiding treatment decisions. The symposium also addressed the impact of COVID-19 on breast cancer care and the need for increased access to care for underserved communities.

Advertisment

Real-World Implications of Trastuzumab Deruxtecan

The RELIEVE study evaluated real-world patients with advanced breast cancer who received trastuzumab deruxtecan (T-DXd; Enhertu). The findings suggest that T-DXd is effective and safe for patients outside of clinical trials. It was also noted that T-DXd is a treatment strategy that should be considered for patients with changes in HER2 status. More data is required to understand the implications of changes in HER2 status.

Conclusion

The San Antonio Breast Cancer Symposium 2023 offered a plethora of new insights and advancements in the field of breast cancer treatment and prevention. From focusing on precision treatment and de-escalation to presenting promising results from various trials, the symposium has set a new benchmark in breast cancer research and therapies. However, further research is recommended for a deeper understanding of these new developments.

Breast Cancer
Advertisment
Chat with Dr. Medriva !